ALL ABOUT DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
A VA study found type 2 diabetes patients stopping GLP-1 drugs regained weight and faced a 22% rise in cardiovascular risks.
A VA study found type 2 diabetes patients stopping GLP-1 drugs regained weight and faced a 22% rise in cardiovascular risks.
A VA study found type 2 diabetes patients stopping GLP-1 drugs regained weight and faced a 22% rise in cardiovascular risks.
A VA study found type 2 diabetes patients stopping GLP-1 drugs regained weight and faced a 22% rise in cardiovascular risks.
A VA study found type 2 diabetes patients stopping GLP-1 drugs regained weight and faced a 22% rise in cardiovascular risks.
A VA study found type 2 diabetes patients stopping GLP-1 drugs regained weight and faced a 22% rise in cardiovascular risks.
Read More
Denali’s Avlayah reduced cerebrospinal fluid heparan sulfate by 91% in a Phase 1/2 trial for pediatric Hunter syndrome patients.
Read More
The CDC updated childhood vaccine guidelines, reducing routine immunizations from 17 to 11 diseases and shifting six vaccines to high-risk groups.
Read More
Linguists and style experts explained that “alternative” implies mutually exclusive choices, while “option” denotes any selectable possibility.
Read More
Congress enacted Most Favored Nation pricing for biologics and specialty drugs on May 12, 2025, aligning U.S. prices with lower international rates.
Read More
CMS finalized a 2.6% increase in Medicare hospital outpatient payment rates for 2026, affecting 4,000 hospitals and 6,000 surgical centers.
Read More
A study finds sarcopenic obesity, excess belly fat with low muscle, raises death risk by 83% in adults over 50.
Read More
The FDA proposed reclassifying Mycobacterium tuberculosis immunity tests from Class III to Class II devices with new special controls.
Read More
A global analysis of 10,000 knee arthritis patients found knee braces, water therapy, and exercise outperform drug treatments in pain relief and function.
Read More
The FDA approved Avlayah (tividenofusp alfa-eknm) for treating neurologic Hunter syndrome in pediatric patients weighing at least 5 kg.
Read More
